Hospital Guide: Guangzhou Concord Cancer Center

I. Hospital overview and vision

Guangzhou Concord Cancer Center is a tertiary oncology specialist hospital in China's Greater Bay Area, founded to deliver international-standard cancer diagnosis, treatment, and rehabilitation. The hospital collaborates with globally recognized institutions such as MD Anderson Cancer Center and Mayo Clinic to adopt evidence-based protocols. Its 550-bed facility spans 37,000 square meters and includes specialized units for radiotherapy, day chemotherapy, and palliative care.

II. Cutting-edge medical technologies

Precision radiotherapy. Probeam Proton Therapy System: one of Asia's first compact proton therapy units, enabling tumor targeting with minimal damage to surrounding tissues. Varian TrueBeam and Halcyon linacs: for intensity-modulated (IMRT) and stereotactic (SBRT) radiotherapy.

Diagnostic and surgical suite. PET/CT-MRI fusion imaging, 3.0T MRI, and the Da Vinci Xi surgical robot for minimally invasive oncology surgery.

Laboratory innovations. A CAP-accredited lab offering NGS genetic testing, liquid biopsies, and PD-L1 biomarker analysis.

III. Flagship departments and expert teams

As the flagship department, it specializes in the diagnosis and medical treatment of solid tumors, with particular expertise in digestive system cancers (gastric, colorectal) and breast cancer. The team develops individualized regimens combining chemotherapy, targeted therapy, and immunotherapy, based on a comprehensive assessment of patient condition and tumor biology. Prof. Qian Chaonan (former Chief Physicist at MD Anderson) specializes in proton therapy for pediatric, central nervous system, and prostate cancers.

Covering multiple surgical oncology domains, the surgery department delivers precise tumor resection with a focus on preserving organ function:

Gastrointestinal surgery. Led by specialists such as Chief Physician Luo Chunsheng and Associate Chief Physician Xie Xiaoming, it excels in the diagnosis and surgical treatment of gastric and colorectal cancers, including minimally invasive procedures that accelerate recovery.

Breast and urological oncology. Dr. Su Pengxi specializes in surgical treatment of breast tumors, adrenal tumors, kidney tumors, and prostate cancer, ensuring both therapeutic efficacy and quality of life after treatment.

Thoracic oncology. Chief Physician Luo Chunsheng also leads the team in managing thoracic tumors and non-tumor diseases, with additional expertise in surgical treatment of hyperhidrosis of the hands and feet.

Anesthesiology and pain management. Directed by Chief Physician Li Yalan, a doctoral supervisor, the department specializes in anesthesia for cardiovascular surgery, perioperative management of elderly patients, and pain control for critically ill or advanced cancer patients, ensuring patient comfort during treatment.

Gynecologic oncology. Associate Chief Physician Zhou Ye focuses on gynecological conditions related to cancer, including menstrual disorders, endometrial lesions, and infertility, providing integrated care for female cancer patients.

Preventive medicine center. Beyond vaccination services, it offers cancer prevention consultations and health risk assessments, meeting the preventive healthcare needs of expat communities.

IV. Guangzhou as a medical hub

Location. Huangpu District, Guangzhou, 40 minutes from Baiyun International Airport (CAN).

Transport. Adjacent to Exit D of Hetangxia Station on Guangzhou Metro Line 14, one of the most convenient options for visitors, with the station directly connected to the hospital area. Direct highway access to Hong Kong and Shenzhen (a 2-hour drive).

Driving and parking. On-site parking is available for private vehicles, with clear signage guiding visitors to the main entrance and outpatient area.

Visa and insurance. 240-hour visa-free transit; direct billing with over 30 international insurers.

V. International patient services

Multilingual coordinators (English, Cantonese, Mandarin). Seamless referrals and second opinions via telemedicine partnerships.